Mesoblast is developing a series of high margin, off the shelf adult stem cell products that are obtained from a single donor, commercially expanded and frozen, and subsequently used in potentially thousands of unrelated, or allogeneic, recipients at the time and place of need.
Quote | Mesoblast Ltd Ord (OTCMKTS:MEOBF)
Last: | $0.6051 |
---|---|
Change Percent: | 0.0% |
Open: | $0 |
Close: | $0.6051 |
High: | $0 |
Low: | $0 |
Volume: | 152,112 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Mesoblast Ltd Ord (OTCMKTS:MEOBF)
2024-04-10 13:29:22 ET Summary Mesoblast Limited has been on a major run recently as its cell therapy candidate is back on track towards potential approval. The company has some upcoming potential catalysts in the quarters ahead and is advancing its pipeline on several fronts. ...
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA has informed the company that following additional consideration the available clinical data from its Phas...
Message Board Posts | Mesoblast Ltd Ord (OTCMKTS:MEOBF)
Subject | By | Source | When |
---|---|---|---|
chartguy89: MEOBF 5.19 Stock Charts $MEOBF 1 Month Chart | chartguy89 | investorshangout | 03/08/2014 6:46:31 PM |
chartguy89: MEOBF Stock Charts Last: -0.13 Thursday, February 27, 2014 at 10:28:22 PM $MEOBF | chartguy89 | investorshangout | 02/28/2014 3:28:33 AM |
News, Short Squeeze, Breakout and More Instantly...
Mesoblast Ltd Ord Company Name:
MEOBF Stock Symbol:
OTCMKTS Market:
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA has informed the company that following additional consideration the available clinical data from its Phas...
NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received firm commitments to complete its pro-rata accelerated non-renounceable entitlement offer that was launch...
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended December 31, 2023. Mesoblast Chief Executi...